Cargando…
Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives
In this era of precision oncology, there has been an exponential growth in the armamentarium of genomically targeted therapies and immunotherapies. Evaluating early responses to precision therapy is essential for “go” versus “no go” decisions for these molecularly targeted drugs and agents that arm...
Autores principales: | Subbiah, Vivek, Chuang, Hubert H., Gambhire, Dhiraj, Kairemo, Kalevi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5373019/ https://www.ncbi.nlm.nih.gov/pubmed/28212290 http://dx.doi.org/10.3390/diagnostics7010010 |
Ejemplares similares
-
Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST
por: Kairemo, Kalevi, et al.
Publicado: (2019) -
Early Response Assessment to Targeted Therapy Using 3′-deoxy-3′[(18)F]-Fluorothymidine ((18)F-FLT) PET/CT in Lung Cancer
por: Kairemo, Kalevi, et al.
Publicado: (2020) -
An Assessment of Early Response to Targeted Therapy via Molecular Imaging: A Pilot Study of 3′-deoxy-3′[(18)F]-Fluorothymidine Positron Emission Tomography (18)F-FLT PET/CT in Prostate Adenocarcinoma
por: Kairemo, Kalevi, et al.
Publicado: (2017) -
Sodium fluoride (Na(18)F) PET Response Criteria in Solid Tumors (NAFCIST): a framework for response assessment in bone tumors
por: Kairemo, K., et al.
Publicado: (2023) -
Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma
por: Gouda, Mohamed A., et al.
Publicado: (2023)